

Doxorubicin-induced cardiotoxicity in adult Indian patients on chemotherapy

Navin Khattry,
Pankaj Malhotra,
Anil Grover¹,
Suresh C. Sharma²,
Subhash Varma

Departments of Internal Medicine,
¹Cardiology and ²Radiotherapy,
Postgraduate Institute of Medical
Education and Research,
Chandigarh, India

Address for correspondence:
Dr. Navin Khattry,
Department of Medical Oncology,
Tata Memorial Cancer Center,
Mumbai, India.
E-mail: nkhattry@gmail.com

ABSTRACT

Background: Doxorubicin-induced cardiotoxicity is widely known to occur at cumulative doses exceeding 450 mg/m². However, very few studies have reported incidence of cardiac dysfunction in patients on chemotherapy with lower cumulative doses. To the best of our knowledge, there is no study carried out so far that has reported the incidence of cardiac dysfunction in adult Indian patients receiving doxorubicin. This study was undertaken to determine the incidence of doxorubicin-induced cardiotoxicity by serial resting echocardiography in patients on chemotherapy and identify risk factors associated with cardiotoxicity. **Materials and Methods:** Patients that were started on doxorubicin-based chemotherapy in the period from January 2000 to June 2001 and had completed at least 300mg/m² cumulative dose were taken in the study. Electrocardiography, chest X-ray and echocardiography were done at baseline, at 300mg/m² and at 450mg/m² cumulative doses of doxorubicin. All patients were evaluated for the presence of the following risk factors: Age >70 years, female sex, preexisting cardiac disease, hypertension, chest wall irradiation, body mass index (BMI) <20 kg/m², Karnofsky performance status, combination chemotherapy with cyclophosphamide and presence of liver disease. Subclinical cardiac dysfunction was defined as ejection fraction fall greater than 10% on follow-up echocardiography. **Results:** Thirty patients satisfied the criterion for being considered for evaluation. One (3%) patient developed congestive cardiac failure, while 8 (27%) patients developed subclinical cardiac dysfunction. Concomitant use of cyclophosphamide significantly increased the risk of cardiac dysfunction ($P = 0.048$), while low BMI (<20 kg/m²) and preexisting cardiac disease showed a trend towards increased risk of cardiac dysfunction ($P = 0.07$ for both). **Conclusion:** Twenty-seven percent of the patients developed subclinical cardiac dysfunction in the cumulative dose range of 300-450 mg/m². This entails regular monitoring for cardiac dysfunction by echocardiography during treatment.

Key words: Doxorubicin, cardiotoxicity, echocardiographic monitoring

DOI: 10.4103/0971-5851.56329

INTRODUCTION

Anthracyclines represent some of the most commonly used anticancer drugs. Major side effects associated with anthracycline use are bone marrow suppression and cardiac toxicity. Cardiac toxicity is accentuated by increasing age (more than 70 years), female sex, combination chemotherapy, mediastinal radiation, previous cardiac disease, hypertension, liver disease and whole body hypothermia.^[1]

Anthracyclines are associated with both acute and chronic cardiotoxicity. Chronic cardiotoxicity in the form of congestive cardiac failure is dose dependent and occurs 4-8 weeks after last anthracycline dose, though it may occur during treatment or years later.^[2] Treatment with doxorubicin may necessitate lifelong cardiac monitoring. The exact causal mechanism of

anthracycline-induced cardiac toxicity remains unclear, but most studies indicate that free radicals are involved.^[1] Clinical parameters^[3] and electrocardiographic^[4] changes are not sensitive and specific in detecting cardiotoxicity. Endomyocardial biopsy,^[5] though gold standard for detecting anthracycline-induced cardiotoxicity, cannot be employed routinely. Echocardiography^[6] and radionuclide^[7] imaging remain good noninvasive techniques to study effects on cardiac function. Though radionuclide studies have been reported to be more sensitive in detecting systolic and diastolic dysfunction, they expose patients to ionizing radiation^[8] and are not widely available. Echocardiography is more easily available, is not dependent on the availability of radioisotopes and is less costly.

There are very few studies^[9-11] reporting cardiac dysfunction in patients while still on chemotherapy. Though the risk

of cardiac dysfunction increases steeply after a cumulative dose of 450-550 mg/m² of doxorubicin is reached, it is not known whether lower cumulative doses also lead to significant cardiac dysfunction warranting very close monitoring.

This study was planned as a preliminary investigation to see whether echocardiography can detect cardiac dysfunction in patients on treatment with doxorubicin and also if there are any identifiable risk factors for cardiac toxicity in Indian patients.

MATERIALS AND METHODS

All newly diagnosed patients aged more than 15 years who were administered doxorubicin for the first time and who gave informed consent were enrolled in the study. All patients were questioned for recent history of hypertension, mediastinal or chest wall irradiation and cardiac or liver disease. Body mass index (BMI) and Karnofsky performance status of all patients were recorded at baseline. A detailed examination of cardiovascular system was done at baseline and at each follow-up. Renal function tests, liver function tests, 12-lead ECG, chest X-ray and echocardiography were done at baseline, at 300 mg/m² and at 400-450 mg/m² cumulative doses of doxorubicin. During echocardiography, fractional shortening and ejection fraction were evaluated, besides other routine parameters. Fractional shortening was calculated by the formula

$$\frac{LVIDd^* - LVIDs^\delta}{LVIDd} \times 100$$

[*LVIDd- Left ventricular internal diameter in diastole

^δ LVIDs- Left ventricular internal diameter in systole],

while ejection fraction was calculated by M-mode and modified Simpson's formula. In order to reduce inter-observer variability, echocardiography was performed by the same physician for each patient at different time points. Intra-observer variability was reduced by taking the mean of three readings during each echocardiography.

All patients included in the study had left ventricular ejection fraction (LVEF) greater than 50% at baseline. Patients with history of coronary artery disease who had regional wall-motion abnormalities at baseline echocardiography or had an acute coronary syndrome within 1 year of cancer diagnosis were excluded from the study.

This study was approved by the ethics committee of the institute.

Statistical analysis

Subclinical cardiac dysfunction was defined as fall of ejection fraction >10% during follow-up echocardiography at 300 mg/m² and/or 400-450 mg/m². This was based on the published guidelines on monitoring for doxorubicin-induced cardiotoxicity.^[6,12] Role of various risk factors was analyzed by using chi-square test and unpaired *t* test. The risk factors studied were age >70 years, female sex, presence of preexisting cardiac disease, hypertension, chest wall or mediastinal irradiation, BMI <20 kg/m², Karnofsky performance status, combination chemotherapy with cyclophosphamide and presence of liver disease. Paired *t* test was used to compare various quantitative clinical parameters recorded at baseline, at 300 mg/m² and 450mg/m² doses of doxorubicin. Multiple logistic regression analysis was done to analyze further the significance of individual risk factors.

RESULTS

Thirty-eight patients were enrolled in the study, from January 2000 to June 2001. Eight patients were excluded as they did not receive full course of chemotherapy due to progression of disease. Thirty patients received at least 300 mg/m² of doxorubicin, while 14 patients received more than 400 mg/m² cumulative dose of doxorubicin. The baseline characteristics of 30 patients are shown in Table 1.

The chemotherapeutic regimens used according to different diagnoses are shown in Table 2. Twenty (66.7%) patients received regimens that included both cyclophosphamide and adriamycin. The most common dose of adriamycin used was 50 mg/m² per cycle of chemotherapy. The schedule of administration of doxorubicin was similar in all patients. All patients received intravenous boluses

Table 1: Baseline characteristics of patients

| Parameter | Mean (SD) | Range |
|---|--------------|-----------|
| Age (yrs) | 44.83 ± 14.2 | (16-72) |
| BMI (kg/m ²) | 23.36 ± 4.3 | (17-35) |
| No. of cycles of chemotherapy received | 7.63 ± 1.7 | (6-10) |
| Cumulative dose of doxorubicin (mg/m ²) | 372.3 ± 79.4 | (300-500) |
| Baseline heart rate | 90.73 ± 11.2 | (72-116) |
| Baseline SBP (mm Hg) | 134.6 ± 11.9 | (110-160) |
| Baseline DBP (mm Hg) | 82.93 ± 9.4 | (70-100) |
| Baseline EF | 63.63 ± 7.04 | (50-77) |
| Baseline FS | 35.12 ± 6.04 | (25-48) |
| BSA (m ²) | 1.6 ± 0.17 | (1.3-2.1) |
| KPS | 71.67 ± 10.9 | (50-90) |

BMI = Body mass index; BSA = Body surface area; SBP = Systolic blood pressure; DBP = Diastolic blood pressure; EF = Ejection fraction; FS = Fractional shortening; KPS - Karnofsky performance status; SD = Standard deviation

Table 2: Diagnosis and schedule of chemotherapy in patients evaluated for doxorubicin-induced cardiac dysfunction

| Diagnosis | No. of pts. (n = 30) | Chemotherapy schedule | Dosing intervals | No. of cycles of chemotherapy |
|--------------------------|----------------------|---|------------------|-------------------------------|
| Non-Hodgkin's lymphoma | 15 (50%) | Cy – 800 mg/m ² Adr – 50 mg/m ² VCR – 1.4 mg/m ² Prn – 60 mg/m ² | 3 weekly | 6-10 |
| Hodgkin's disease | 5 (16.6%) | Adr – 25 mg/m ² Blm – 10 U/m ² D1, D15 VBI – 6 mg/m ² DCZ – 375 mg/m ² | 4 weekly | 6-8 |
| Breast carcinoma | 4 (13.3%) | Cy – 600 mg/m ² Adr – 50 mg/m ² 5FU – 600 mg/m ² | 3 weekly | 6 |
| Multiple myeloma | 2 (6.67%) | VCR – 0.4 mg Adr – 9 mg/m ² D1-D4 Dex = 40 mg | 3 weekly | 6-8 |
| Gastric carcinoma | 2 (6.67%) | 5FU – 600 mg/m ² Adr – 50 mg/m ² MMC – 6 mg/m ² | 3 weekly | 6 |
| Hepatocellular carcinoma | 1 (3.33%) | 5FU – 600 mg/m ² Adr – 50 mg/m ² MMC – 6 mg/m ² | 3 weekly | 6 |
| Uterine leiomyosarcoma | 1 (3.33%) | Cy – 600 mg/m ² VCR – 1.4 mg/m ² Adr – 50 mg/m ² | 3 weekly | 6 |

Cy = Cyclophosphamide; Adr = Adriamycin; 5FU = 5 fluorouracil; Blm = Bleomycin; VCR = Vincristine; Dex = Dexamethasone; Prn = Prednisolone; MMC = Mitomycin C; DCZ = Dacarbazine, D1 = Day 1; D4 = Day 4; D15 = Day 15

of doxorubicin over 10 minutes. Three patients had postponement of cycle of chemotherapy by 1 week due to neutropenia. However, all 30 patients completed the designated number of cycles of chemotherapy according to their protocol.

The prevalence of various risk factors is shown in Table 3. The most commonly associated risk factor was the concomitant use of cyclophosphamide (66.7%).

Nine (30%) patients had greater than 10% fall in LVEF as indicated in follow-up echocardiography (group A). Twenty-one patients had either no change or less than 10% fall in LVEF (group B). In group A, 1 (3%) patient developed congestive heart failure after receiving 450 mg/m² cumulative dose of doxorubicin, while 8 (27%) patients developed subclinical cardiac dysfunction at 300 mg/m² (4 patients) or 400-450 mg/m² (4 patients) cumulative dose. There was no significant difference in systolic and diastolic blood pressure in groups A and B — at baseline, 300 mg/m² and 400-450 mg/m² cumulative dose of doxorubicin as analyzed by paired *t* test. Similarly no significant changes were seen in ECG and chest x-ray of patients at above dose levels. No patient developed acute cardiac dysfunction after any dose of doxorubicin.

Table 3: Prevalence of various risk factors among patients evaluated for cardiac dysfunction

| Risk factors | No. of patients (%) (n = 30) |
|---|------------------------------|
| Hypertension | 9 (30) |
| Mediastinal/chest wall irradiation | 4 (13.33) |
| Heart disease | 6 (20) |
| Combination therapy with cyclophosphamide | 20 (66.67) |
| Age > 70 yrs | 3 (10) |
| Liver disease | 0 (0) |
| BMI ≤ 20 kg/m ² | 8 (26.6%) |

Age >70 years, sex, hypertension, concomitant or previous use of mediastinal/chest wall irradiation and Karnofsky performance status did not correlate significantly to the development of cardiac dysfunction (*P* > 0.1). However, multiple logistic regression analysis showed that concomitant chemotherapy with cyclophosphamide significantly correlated with increased incidence of doxorubicin-induced cardiotoxicity (regression coefficient = 3.22, *P* = 0.048). Similarly lower BMI (<20 kg/m²) and presence of associated heart disease correlated with increased incidence of subclinical cardiotoxicity (regression coefficient = -4.321,

$P = 0.07$; $r = 4.09$, $P = 0.07$), though they did not reach statistical significance.

DISCUSSION

It is a well-known fact that incidence of cardiac dysfunction rises steeply if cumulative dose of doxorubicin exceeds 550 mg/m². However, very few studies have evaluated development of asymptomatic cardiac dysfunction in the lower cumulative dose range. The present study was aimed to find the incidence of both subclinical and clinical cardiac dysfunction at lower cumulative dose range, viz., 300 to 450 mg/m², by serial echocardiographic measurement and identify any known risk factors associated with cardiac dysfunction.

The incidence of clinically diagnosed doxorubicin-induced congestive heart failure was 3% in our study and is in general agreement with the range of 0.4% to 9% reported by others.^[13,14] Though the incidence of congestive cardiac failure was low, incidence of subclinical cardiac dysfunction in our study was high, viz., 27% (8 of the 30 patients). This observation is consistent with studies that have evaluated subclinical cardiac dysfunction. Palmeri *et al.*,^[9] in their group of 48 patients that received a mean dose of doxorubicin of 338 mg/m² found that 63% of their patients had some fall in LVEF as measured by rest and exercise radionuclide angiography. Similarly Dresdale *et al.*,^[10] in 87 asymptomatic patients that received >430 mg/m² of doxorubicin found abnormal LVEF at rest by radionuclide angiogram in 21% of patients. Exercise studies in their study identified an additional 31% of patients. Mohta *et al.*,^[15] in pediatric patients observed that 30% of the patients had significant cardiac dysfunction on echocardiographic evaluation at a mean cumulative dose of 365 mg/m². Similarly Agarwala *et al.*,^[11] observed that 40% of children undergoing doxorubicin-based chemotherapy developed subclinical cardiac dysfunction at a cumulative dose of 180-200 mg/m².

Cumulative dose of doxorubicin is the single most important determinant of cardiac toxicity. Lefrak *et al.*,^[16] in their study found that incidence of congestive cardiac failure rose to unacceptably high levels when cumulative dose of drug exceeded 550 mg/m², viz., from 4% at 500-550 mg/m² to 18% at 551-600 mg/m² and to 36% at a dose of 601 mg/m² or more. Von Hoff *et al.*,^[17] found that cumulative probability of developing drug-induced heart failure was 0.03 at 400 mg/m², 0.07 at 550 mg/m² and 0.18 at 700 mg/m². In the present study, at 300 mg/m² cumulative dose of doxorubicin, 16% developed subclinical cardiac dysfunction; and at 450 mg/m², 28.8% of patients develop cardiac dysfunction. This difference did not reach statistical significance possibly due to the small size of the study population ($\chi^2 = 0.26$, $P > 0.1$).

The present study found statistically significant association of concomitant use of doxorubicin and cyclophosphamide with cardiac dysfunction (regression coefficient = 3.22, $P = 0.048$). Similar inference was drawn by Minow *et al.*,^[13] and von Hoff *et al.*,^[17] in their studies, and it is now standard practice to use lower cumulative dose ceiling in patients exposed to both cyclophosphamide and doxorubicin.

Malnutrition has also been identified as a risk factor for doxorubicin-induced cardiotoxicity. A study by Obama *et al.*,^[18] found that cardiac toxicity was more in those children that were malnourished ($P < 0.05$). Similarly Mohta *et al.*,^[15] in Indian pediatric cancer patients observed that children that developed cardiac dysfunction had significantly lower height and weight for age compared to those that remained normal. Though we did not do a formal nutritional assessment in our patients, we analyzed the incidence of cardiac dysfunction in patients with lower BMI (<20 kg/m²) as a surrogate marker of nutritional status. Patients with BMI <20 kg/m² were shown in our study to have increased risk of cardiac dysfunction, though the association did not reach statistically significant level, probably due to the small sample size (regression coefficient = -0.432, $P = 0.07$). How poor nutritional status affects cardiotoxicity is not clear, though it has been reported that micronutrients like carnitine,^[19] selenium^[20] and vitamin E^[21] have ameliorated cardiotoxicity of anthracyclines.

In our study, 6 (20%) patients had medical history of coronary artery disease. All 6 patients had LVEF greater than 50% at baseline with no regional wall motion abnormalities in echocardiogram. Two out of 9 patients with doxorubicin-induced cardiac dysfunction had coronary artery disease. Multiple logistic regression analysis showed that cardiac disease as a risk factor almost reached statistical significance in contributing to doxorubicin-induced cardiotoxicity in our patients (regression coefficient = 4.088, $P = 0.07$). The results are similar to those in the studies by von Hoff *et al.*,^[17] and Minow *et al.*,^[13] who found that patients with preexisting cardiac disease had increased probability of developing cardiac dysfunction due to doxorubicin.

The present study due to its small sample size did not find hypertension, advanced age, receiving mediastinal irradiation, sex and performance status to be risk factors for cardiotoxicity.

The high incidence of subclinical cardiac dysfunction in our patients reinforces the need for strict monitoring of patients on doxorubicin during treatment.

In conclusions, the present study suggests that subclinical cardiac dysfunction due to doxorubicin is high in the cumulative dose range of 300-450 mg/m². This entails regular monitoring for cardiac dysfunction by echocardiography during treatment.

REFERENCES

1. Singal PK, Iljaskovic N. Doxorubicin induced cardiomyopathy. *N Engl J Med* 1998;339:900-5.
2. Steinherz LJ, Steinherz PG, Tan C, Heller G, Murphy ML. Cardiac toxicity 4-20 yrs after completing anthracycline therapy. *JAMA* 1991;266:1672-7.
3. Haq MM, Legha SS, Choski J, Hortobagyi GN, Benjamin RS, Ewer M, *et al.* Doxorubicin induced heart failure in adults. *Cancer* 1985;56:1361-5.
4. Praga C, Beretta G, Ligo PL. Adriamycin cardiotoxicity: A survey of 1273 patients. *Cancer Treat Rep* 1979;63:827-34.
5. Nortensen SA, Olsen HS, Baandrup U. Chronic anthracycline cardiotoxicity: Hemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease. *Br Heart J* 1986;55:274-82.
6. Ganz WI, Sridhar KS, Ganz SS, Gonzalez R, Chakko S, Seratini A. Review of tests of monitoring doxorubicin induced cardiomyopathy. *Oncology* 1996;53:461-70.
7. Piver MS, Marchetti DL, Parthasarathy KL, Bakshi S, Reese P. Doxorubicin hydrochloride cardiotoxicity evaluated by sequential radionuclide angiography. *Cancer* 1985;56:76-80.
8. Bristow MR, Lopez MB, Mason JW, Billingham ME, Winchester MA. Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. *Cancer* 1982;50:32-41.
9. Palmeri TS, Bonow RO, Myers CE, Seipp C, Jenkins J, Green MV, *et al.* Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography. *Am J Cardiol* 1986;58:607-13.
10. Dresdale A, Bonow RO, Wesley R, Palmeri ST, Barr L, Mathison D, *et al.* Prospective evaluation of doxorubicin induced cardiomyopathy resulting from post surgical adjuvant treatment of patients with soft tissue sarcomas. *Cancer* 1983;52:51-60.
11. Agarwala S, Kumar R, Bhatnagar V, Bajpai M, Gupta DK, Mitra DK. High incidence of adriamycin cardiotoxicity in children even at low cumulative doses: Role of radionuclide cardiac angiography. *J Pediatr* 2000;35:1786-9.
12. Steinherz LJ, Graham T, Hurwitz R, Sondheimer HM, Schwartz RG, Shaffer EM, *et al.* Guidelines for cardiac monitoring of children during and after anthracycline therapy: Report of Cardiology committee of children cancer study group. *Pediatrics* 1992;89:942-9.
13. Minow RA, Benjamin RS, Lee ET, Gottlieb JA. Adriamycin cardiomyopathy-risk factors. *Cancer* 1977;39:1397-402.
14. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The pediatric oncology group experience. *J Clin Oncol* 1997;15:1544-52.
15. Mohta R, Saxena A, Jain Y, Gupta S, Thavaraj V, Narain S, *et al.* Anthracycline associated cardiac toxicity in children with malignancies. *Indian Pediatr* 2002;39:549-55.
16. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinico pathological analysis of adriamycin cardiotoxicity. *Cancer* 1973;32:302-14.
17. VonHoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, *et al.* Risk factors for doxorubicin induced congestive heart failure. *Ann Intern Med* 1979;91:710-7.
18. O'Bama M, Cangif A, Van Eys J. Nutritional status and anthracycline cardiotoxicity in children. *South Med J* 1983; 76:577-8.
19. Vick JA, Garattini S, Donneli MG, De Felici SL, Sanzari NP. Prevention of adriamycin induced toxicity with carnitine. *Physiologist* 1975;5:221-4.
20. Ferrans VJ. Overview of cardiac pathology in relation to anthracycline cardiotoxicity. *Cancer Treat Rep* 1978;62:955-61.
21. Sonneveld P. Effect of alpha tocopherol on the cardiotoxicity of adriamycin in the rat. *Cancer treat Rep* 1978;62:1033-6.

Source of Support: Nil, Conflict of Interest: None declared.

Author Help: Online submission of the manuscripts

Articles can be submitted online from <http://www.journalonweb.com>. For online submission, the articles should be prepared in two files (first page file and article file). Images should be submitted separately.

1) First Page File:

Prepare the title page, covering letter, acknowledgement etc. using a word processor program. All information related to your identity should be included here. Use text/rtf/doc/pdf files. Do not zip the files.

2) Article File:

The main text of the article, beginning with the Abstract to References (including tables) should be in this file. Do not include any information (such as acknowledgement, your names in page headers etc.) in this file. Use text/rtf/doc/pdf files. Do not zip the files. Limit the file size to 400 kb. Do not incorporate images in the file. If file size is large, graphs can be submitted separately as images, without their being incorporated in the article file. This will reduce the size of the file.

3) Images:

Submit good quality color images. Each image should be less than **2048 kb (2 MB)** in size. The size of the image can be reduced by decreasing the actual height and width of the images (keep up to about 6 inches and up to about 1800 x 1200 pixels). JPEG is the most suitable file format. The image quality should be good enough to judge the scientific value of the image. For the purpose of printing, always retain a good quality, high resolution image. This high resolution image should be sent to the editorial office at the time of sending a revised article.

4) Legends:

Legends for the figures/images should be included at the end of the article file.